> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# NIPRO launches expanded hemodialysis with ELISIO-HX
- URL: https://med-techinsights.com/nipro-launches-expanded-hemodialysis-with-elisio-hx/
- Published: 2026-08-18T11:49:52.000Z
- Updated: 2026-10-23T02:27:52.000Z
- Description: NIPRO, through its subsidiary Nipro Medical Corporation, has announced the U.S. commercial launch of ELISIO-HX, a medium-cutoff dialyser featuring super high-flux membrane technology. Enabled by the recent FDA 510(k) clearance of ELISIO-HX, NIPRO is introducing its expanded hemodialysis approach wit
- Author: Oliver Johnson
- Tags: Medical Device Manufacturing, News

NIPRO, through its subsidiary [**Nipro Medical Corporation**](https://www.nipro-group.com/en/nipro-medical-corporation?ref=med-techinsights.com), has announced the U.S. commercial launch of ELISIO-HX, a medium-cutoff dialyser featuring super high-flux membrane technology.

Enabled by the recent FDA 510(k) clearance of ELISIO-HX, NIPRO is introducing its expanded hemodialysis approach with a super high-flux membrane, or HDs in short, to dialysis providers nationwide.

The company says the launch of ELISIO-HX represents an important milestone in kidney care and reflects NIPRO’s commitment to making advanced dialysis technologies more accessible to dialysis providers and patients across the country.

According to the company, dialysis providers have typically sought ways to expand the removal of larger middle molecules, substances associated with inflammation, and other complications that are not effectively cleared by conventional high-flux dialysis. Broader adoption of therapies designed to address this challenge has been limited due to supply constraints, high costs, operational complexity, and infrastructure requirements.

Nipro says that with the introduction of ELISIO-HX, U.S. providers now have greater access to an expanded hemodialysis therapy with a strong global track record and robust supply capabilities that enhances middle molecule removal. The membrane incorporates a highly controlled and precisely engineered pore structure that is designed to extend the removal profile of larger middle molecules while maintaining albumin retention, an important consideration in preserving patients’ nutritional status.

“Providers have sought a scalable way to improve middle-molecule clearance, but supply constraints, operational complexity and infrastructure requirements have impacted adoption rates in the U.S.,” said James McGetrick, President of North America for Nipro Medical Corporation. “The ELISIO-HX is designed to help overcome those barriers, making this approach accessible through existing dialysis delivery models and at a scale that has not previously been possible.”

“Every advancement in dialysis should be measured by its potential to improve the patient experience,” said Dr. Jeff Giullian, Chief Medical Officer for DaVita. “The availability of ELISIO-HX expands the range of treatment options available to nephrologists and the patients they care for, bringing an important innovation into routine practice. More choice enables more individualised care, and that’s ultimately what patients deserve.”

The U.S. introduction builds on NIPRO’s global experience with ELISIO-HX across Asia, Europe, and Latin America, where the technology has been used in a variety of healthcare settings.